Tolerability, safety, and efficacy of adjunctive brivaracetam for focal seizures in older patients: A pooled analysis from three phase III studies [PDF]
, 2016 Introduction: This analysis was conducted to assess the tolerability, safety, and efficacy of brivaracetam (BRV) for adjunctive treatment of focal (partial-onset) seizures in patients aged ≥65 years.
Brodie, Martin J. +4 more
core +1 more source
Mediterranean Journal of Clinical Psychology, 2022 Background: Nonadherence to homework assignments is a frequent problem among patients with depression during cognitive-behavioral therapy (CBT). The present study investigated the effects of two additional treatment components of CBT: a placebo and SMS ...
Nina Jurinec, Anne Schienle
doaj +1 more source
The Ethics of Placebo-controlled Trials: Methodological Justifications [PDF]
, 2013 The use of placebo controls in clinical trials remains controversial. Ethical analysis and international ethical guidance permit the use of placebo controls in randomized trials when scientifically indicated in four cases: (1) when there is no proven ...
Grady, Christine, Millum, Joseph
core +1 more source
Jurnal Psikologi, 2019 Mindfulness practice is being promoted in Western countries as a means to improve one’s ability to restrain aggression under the “depleted” condition. The applicability of this framework in non-Western settings is yet to be determined. In this experiment
Cleoputri Al Yusainy, Wahyu Wicaksono
doaj +1 more source
Sham Acupuncture Is Not Just a Placebo
Journal of Acupuncture & Meridian Studies, 2022 Sham acupuncture should have two distinct features: first, it must be morphologically similar to verum acupuncture for blinding purposes, and second, it must not exert physiologically expected effects of verum acupuncture.
Tae-Hun Kim +2 more
doaj +1 more source
A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis.
New England Journal of Medicine, 2006 BACKGROUND Natalizumab is the first alpha4 integrin antagonist in a new class of selective adhesion-molecule inhibitors. We report the results of a two-year phase 3 trial of natalizumab in patients with relapsing multiple sclerosis.
C. Polman +13 more
semanticscholar +1 more source
Superpulsed low-level laser therapy protects skeletal muscle of mdx mice against damage, inflammation and morphological changes delaying dystrophy progression. [PDF]
, 2014 Aim: To evaluate the effects of preventive treatment with low-level laser therapy (LLLT) on progression of dystrophy in mdx mice. Methods: Ten animals were randomly divided into 2 experimental groups treated with superpulsed LLLT (904 nm, 15 mW, 700 Hz ...
A Gur +60 more
core +2 more sources
Ocrelizumab versus Placebo in Primary Progressive Multiple Sclerosis
New England Journal of Medicine, 2017 BACKGROUND An evolving understanding of the immunopathogenesis of multiple sclerosis suggests that depleting B cells could be useful for treatment. We studied ocrelizumab, a humanized monoclonal antibody that selectively depletes CD20‐expressing B cells,
X. Montalban +21 more
semanticscholar +1 more source
Demonstration of safety of intravenous immunoglobulin in geriatric patients in a long-term, placebo-controlled study of Alzheimer's disease. [PDF]
, 2016 INTRODUCTION:We present safety results from a study of Gammagard Liquid intravenous immunoglobulin (IGIV) in patients with probable Alzheimer's disease. METHODS:This was a placebo-controlled double-blind study.
Aisen, Paul +8 more
core +2 more sources
Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis.
New England Journal of Medicine, 2010 BACKGROUND Nonalcoholic steatohepatitis is a common liver disease that can progress to cirrhosis. Currently, there is no established treatment for this disease.
A. Sanyal +15 more
semanticscholar +1 more source